On rotary tablet presses, polyherbal extract powders of this type present a dual processing liability: low particle yield pressure and pronounced moisture uptake during dwell. Jingfang Jiedu Powder veterinary grade API is not a single crystalline compound but a polydisperse extract matrix in which polysaccharides, phenylpropanoids, saponins, and residual plant fibers coexist; this heterogeneity prevents the use of direct compression unless the API is coprocessed with a hydrophobic carrier. Lot-to-lot variation in residual moisture, particle size distribution, and extract ratio must be measured before tablet development because a shift in D90 from 150 µm to 250 µm can reduce blend flow function coefficient below the threshold required for high-speed tablet presses. The core formulation for a compressed tablet is developed as a starting range rather than a fixed specification: 20–35% w/w Jingfang Jiedu Powder extract, 25–40% microcrystalline cellulose, 15–25% dibasic calcium phosphate dihydrate, 2–5% croscarmellose sodium, and 2–4% povidone K30.

Granulation is performed in a high-shear granulator with a 65 L bowl. The dry excipients and API are charged and mixed at impeller speed 150–250 rpm and chopper speed 1000–1500 rpm for 3–5 min, after which purified water or a 30% ethanol-water granulating fluid is added at 5–10% w/w of the dry charge. The endpoint is determined by power consumption stabilization and by hand-squeeze crumble; the wet mass is discharged through a 4 mm screen and dried in a fluid-bed drier at inlet air temperature 50±5 °C until loss on drying reaches 3.0–5.0%. Dried granules are milled through a 0.8–1.0 mm Conidur screen, then lubricated with magnesium stearate 0.5–1.0% w/w in a bin blender at 10–15 rpm for 2–3 min. Compression on a 19-station rotary press targets tablet hardness 50–80 N, friability ≤1.0%, and disintegration ≤15 min in water at 37±2 °C. An aqueous HPMC/PEG film coat may be applied at 8–12% weight gain to mask bitterness and reduce surface tack, provided the coating pan inlet temperature does not exceed 55 °C.

Compliance is assessed against the Chinese Veterinary Pharmacopoeia 2020 tablet monograph for weight variation, disintegration, and microbial limits; uniformity of dosage units is evaluated by USP <905> or the CVP equivalent. If the label claims a quantified marker, HPLC release testing must be validated under VICH GL2, and stability data under VICH GL3 should bracket the proposed storage interval. The terminal product is a pale tan to brown uncoated or film-coated tablet for oral administration to swine, cattle, or poultry, packed in HDPE containers with desiccant when the coating is absent.

What Limits Sterile Filtration Throughput in Aqueous Parenterals?

Membrane fouling rather than absolute solubility is typically the rate-limiting unit operation for aqueous parenterals prepared from this extract. At 2–5% w/v in Water for Injection, the polysaccharide and saponin fractions form colloidal aggregates that block 0.22 µm PES membranes after only 4–8 L/m² at 20 °C, a throughput that is too low for commercial aseptic filling. A prefiltration train of 5 µm glass fiber followed by 0.45 µm PVDF is mandatory before terminal membrane filtration. The solvent system requires a solubilizer selected by phase-solubility screening; sulfobutyl ether β-cyclodextrin at 10–20% w/v in 10 mM phosphate buffer pH 6.5 is a candidate, but published data for this specific botanical injection is limited and must be generated before scale-up. The extract also contains low levels of heat-labile lipophilic material that can precipitate as a fine haze upon cooling, so aging at 10–15 °C for 2 h after dissolution is applied to coarsen and remove these particulates.

Aseptic processing is preferred over terminal steam sterilization because autoclaving at 121 °C for 15 min can degrade volatile monoterpenes and cause unacceptable browning. The manufacturing area is classified as ISO 14644-1 class 7 with local filling in class 5; the solution is dissolved at 35–40 °C under nitrogen, cooled, clarified through a charged depth filter, and terminally filtered through 0.22 µm PVDF into depyrogenated 10 mL or 100 mL Type I glass vials. Fill volume and subvisible particulate counts are monitored according to USP <788> for parenteral products or the CVP injection monograph. Residual solvent levels must conform to VICH GL18(R2), and the aseptic process must be validated under VICH GL1.

Compliance under the Chinese Veterinary Pharmacopoeia 2020 injection monograph requires sterility, bacterial endotoxin limits, pH, particulate matter, and extractable volume. The finished injectable is indicated only where the clinical benefit justifies parenteral administration because oral dosage forms present a wider safety margin and avoid the stability constraints associated with aqueous botanical extracts. The terminal product is a clear to slightly opalescent sterile solution in sealed glass ampoules or vials, stored below 25 °C and protected from light.

Capsule Fill Weight Control Under High-Humidity Powder Handling

Hard gelatin and HPMC capsules are sensitive to moisture transfer from hygroscopic fill powders. The extract should not be filled directly because its cohesive strength and moisture affinity cause flow stoppage in dosator pins and erratic fill weights at relative humidity above 40% RH. Roller compaction is therefore used to produce a densified granule with improved flow and reduced surface exposure. The formulation for a hard shell capsule includes 30–50% w/w Jingfang Jiedu Powder extract, 30–45% lactose monohydrate, 10–20% microcrystalline cellulose, 2–4% croscarmellose sodium, 0.5–1.0% colloidal silicon dioxide, and 0.5–1.0% magnesium stearate. The preblend is roller-compacted at roll gap 1.5–2.5 mm and hydraulic pressure 80–120 bar; the compact is milled through a 1.0 mm screen, and fines below 150 µm are recompacted to maintain consistent granule density.

An automatic capsule machine with tamping pin stations is operated at 18–22 °C and ≤40% RH, with target fill weight 350–500 mg for size 1 capsules. Weight variation at a machine speed of 60,000 capsules/h should remain below ±5%; if variation exceeds this range, pin height and powder bed depth are adjusted in 0.5 mm increments. Dissolution is determined using USP <711> apparatus 2 at 50 rpm in 0.1 M HCl at 37±2 °C; not less than 75% of the marker component should release within 45 min, unless the CVP capsule monograph specifies otherwise. Terminal hard gelatin capsules require desiccant protection in HDPE bottles to prevent shell embrittlement; HPMC capsules are less prone to crosslinking and are preferred if aldehyde-containing extract fractions are suspected.

Compliance is assessed under the Chinese Veterinary Pharmacopoeia 2020 capsule monograph for weight variation, disintegration, and microbial attributes. If delayed disintegration occurs after storage at 40 °C/75% RH, gelatin crosslinking or moisture migration should be investigated by DSC or equilibrium moisture analysis. The terminal product is an oral capsule for individual dosing of pigs, calves, or foals; the label must state the extract ratio to enable dose conversion from the crude powder monograph.

When the route of administration is a direct in-feed powder, particle segregation and dusting become the dominant technical risks. The neat API is too cohesive for uniform distribution in complete feed at low inclusion rates, so a pre-blend is prepared by geometric dilution with ground corn starch or spray-dried glucose monohydrate at an API-to-carrier ratio of 1:5 to 1:10 w/w. The carrier is conditioned to a moisture content below 5.0% and sieved through 500 µm mesh before loading. The blended powder is targeted to have a D90 below 150 µm to prevent sift-out in feed mixers, while the API particle size is confirmed by laser diffraction if dry dispersion is used.

Mixing is carried out in a horizontal ribbon blender at 60–70% of gross capacity and rotor speed 20–30 rpm for 15–20 min. Blend uniformity samples are taken from 10 points with a thief sampler; the coefficient of variation for the marker compound should not exceed 5.0%. The mixed powder is discharged through a 1.5 mm screen and packed in 1 kg, 5 kg, or 25 kg multiwall paper bags with an inner LDPE liner. If the API is sourced as a concentrated extract, the label must state the extract ratio and the corresponding dose equivalence to the Jingfang Jiedu Powder crude monograph, because omission of this ratio leads to underdosing or overdose in field use.

Compliance under the Chinese Veterinary Pharmacopoeia 2020 powder monograph includes loss on drying, foreign matter, heavy metals, and microbial enumeration. Ready-to-feed powder for poultry or swine should be packed with desiccant in humid climates and stored below 25 °C in a dry warehouse. The terminal product is a free-flowing oral powder intended for uniform blending into complete feed, not for direct parenteral use.

Fluid-Bed Granulation Endpoints for Soluble Herbal Intermediate

Top-spray fluid-bed granulation is selected when the finished article must dissolve rapidly in drinking water and retain sufficient bulk density for sachet filling. The API is blended with sucrose or maltodextrin at 40–60% w/w and povidone K30 at 2–4% w/w before fluidization. The granulating fluid is purified water at 10–15% w/w of the dry charge; inlet air temperature is held at 60±5 °C, product temperature at 35–40 °C, atomization air pressure 1.5–2.0 bar, and spray rate 10–20 g/min per nozzle. The endpoint is reached when product loss on drying reaches 2.5–4.0% and the granule fraction between 16 mesh and 40 mesh exceeds 80%. Overwetting must be avoided because the extract’s water-soluble fraction can form hard lumps that resist disintegration and reduce dissolution yield.

The granules are cooled to 25 °C before discharge and passed through a 1.0 mm sizing screen; fines below 150 µm are recycled or discarded. Dissolution in tap water at 25 °C should yield a clear-to-slightly-opalescent dispersion without sediment within 5 min under gentle stirring. If sedimentation occurs, polysorbate-80 may be added at 0.1–0.5% w/w to reduce surface tension and aid wetting. The finished granules are filled into 50 g or 100 g sachets of PET/aluminum/LDPE laminate to protect against oxygen and moisture ingress. Granule size distribution, moisture, and assay are tested per batch.

Compliance follows the Chinese Veterinary Pharmacopoeia 2020 granule monograph for granule size distribution, loss on drying, and microbial limits. The terminal product is administered after reconstitution in drinking water for swine or poultry; dosing calculation uses the species-specific posology from the crude powder monograph corrected for extract ratio. The sachets should be stored below 25 °C and 60% RH, and any unused reconstituted liquid should be discarded after 24 h unless preservative efficacy has been validated.

If the Carrier Premix Contains Ionic Trace Minerals, Segregation Testing Becomes Mandatory

Premix carriers containing ferrous sulfate monohydrate, copper sulfate pentahydrate, or choline chloride can induce discrete particle interactions with the extract that are not observed in inert carriers. Free moisture released by these salts at relative humidity above 45% RH can dissolve part of the extract and cause darkening, clumping, and assay loss. The extract should therefore be premixed at 5–10% w/w onto a coated calcium carbonate or starch-based carrier that has been dried to ≤3.0% moisture. Food-grade mineral oil at 1–2% w/w may be applied to the carrier to control dust and to reduce API adhesion to mixer surfaces, but the oil type and peroxide value must be controlled to avoid oxidative degradation of lipophilic marker compounds.

Mixing is performed in a double-helix or paddle mixer with 60–75% fill and shaft speed 20–40 rpm for 15–20 min; active uniformity is assessed by NIR or HPLC at 10 sampling points, with a coefficient of variation below 5.0%. Bulk density, particle size distribution, and segregation potential are measured before bulk release. Sifting segregation is measured according to ASTM D6940-20; the API concentration difference between top and bottom fractions after 20 simulated transfer drops should not exceed 10% relative. If segregation exceeds this limit, the carrier particle size distribution must be narrowed or the oil binder increased by 0.5% increments.

Compliance for the terminal premix includes the Chinese Veterinary Pharmacopoeia 2020 premix monograph for uniformity of dosage units, heavy metals, and microbial limits. The finished premix is packed in 20 kg paper bags with an inner liner and stored below 25 °C and 60% RH. If trace mineral supplements are required in the same feed, they should be added as separate meals or at different manufacturing timepoints to avoid direct contact between the extract and free-flowing inorganic salts. This separation prevents localized moisture transfer and extends the useful blending window in feed mills.

Mechanistically, the dissolution of Jingfang Jiedu Powder in aqueous oral liquids follows two separate kinetic regimes. The polysaccharide, saponin, and oligosaccharide fractions hydrate within minutes under mild agitation, while the lipophilic phenylpropanoid fraction forms a fine dispersion that can adhere to the container wall unless a cosolvent or inclusion agent is present. A production oral solution is therefore formulated with 5–10% w/v API, 10–20% v/v propylene glycol, 5–10% v/v ethanol, 0.1–0.2% w/v potassium sorbate, and 0.05–0.1% w/v sodium benzoate in purified water; the pH is adjusted to 5.5–6.0 with citric acid or sodium hydroxide. The selection of ethanol content must comply with regional residue limits for food-producing species, and VICH GL18 residual solvents should be referenced for batch release.

Manufacturing charges purified water at 40–45 °C into a jacketed stainless-steel vessel equipped with a bottom-mounted homogenizer. The API is added through a 500 µm screen to avoid lumping, and the mixture is circulated through a colloid mill or high-shear rotor-stator at 3000 rpm for 20–30 min. The liquid is cooled to 10–15 °C and held for 2 h to settle fine particles, then filtered through 1.2 µm polypropylene depth media. The filtrate is filled into 1 L HDPE bottles or 5 L jerricans, headspaced with nitrogen, and sealed. In-use stability is assessed by measuring assay and microbial counts after 7 days at 25 °C with the container opened daily; published data for this specific formulation are limited, so preservative efficacy testing under USP <51> should be performed before assigning an open-container shelf life.

Compliance under the Chinese Veterinary Pharmacopoeia 2020 oral liquid monograph includes pH, relative density, total solids, and preservative efficacy. The terminal product is intended for oral administration via drinking water or drench, not for parenteral use. It is stored below 25 °C, protected from light, and labeled with the extract ratio and species-specific dosing instructions.